







2015 Operating Grants Competition Results

Researcher	Project Title	Funding Details
Addison, Christina Ottawa Hospital Research Institute	Towards novel effective combination therapy for KRAS mutant non-small cell lung cancer	\$120,000/ 2 years
Affar, ElBachir Research Centre, Hôpital Maisonneuve-Rosemont	Roles of the tumor suppressor BAP1 in genomic stability	\$120,000/ 2 years <i>Funded by the Cancer Research Society's Environment-Cancer Fund™, in partnership with Read for the Cure Read for the Cure</i>  
Ailles, Laurie Princess Margaret Cancer Centre	Characterization of epigenetic deregulation in clear cell renal cell carcinoma	\$120,000/ 2 years
Attisano, Liliana University of Toronto	Defining the role of NUAAs in colorectal cancer	\$120,000/ 2 years
Auer, Rebecca Ottawa Hospital Research Institute	Investigating the role of surgery-induced Myeloid Derived Suppressor Cells in postoperative immune suppression and cancer recurrence	\$119,999/ 2 years
Autexier, Chantal Lady Davis Institute	ALTerred telomere biology in breast cancer	\$120,000/ 2 years



2015 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Babak, Tomas</i> Queen's University	Characterizing cis-regulatory drivers of ovarian cancer	\$119,086/ 2 years
<i>Bahlis, Nizar Jacques</i> University of Calgary - Southern Alberta Cancer Research Institute	Mechanisms of resistance to immunomodulatory (IMiDs) drugs in multiple myeloma: role of Interferon response	\$120,000/ 2 years
<i>Basik, Mark</i> Lady Davis Institute	Dissecting the tumour suppressive functions of SPEN in ER+ breast cancers	\$120,000/ 2 years <i>Funded in partnership with the Quebec Breast Cancer Foundation</i> 
<i>Bernier, Gilbert</i> Research Centre, Hôpital Maisonnette-Rosemont	Pharmaceutical inhibition of cancer stem cell renewal for the treatment of glioblastoma multiforme	\$120,000/ 2 years
<i>Bérubé, Nathalie</i> The University of Western Ontario	Modeling chromatin dysfunction in gliomagenesis	\$120,000/ 2 years
<i>Brand, Marjorie</i> Ottawa Hospital Research Institute	Pre-clinical evaluation of a novel targeted epigenetic therapy for childhood T-cell acute lymphoblastic leukemia (T-ALL)	\$120,000/ 2 years

2015 Operating Grants Competition Results

Researcher	Project Title	Funding Details
Brodt, Pnina McGill University Health Centre	Role of the stroma in pancreatic ductal adenocarcinoma progression and metastasis.	\$ 119, 800/ 2 years <i>Funded in partnership with the Charlotte Légaré Memorial Fund</i>  Charlotte Légaré Memorial Fund
Chang, Hong University Health Network	Role of miRNA(s) in sensitizing anti-myeloma activity of PRIMA-1	\$120,000/ 2 years
Claing, Audrey Université de Montréal	Role of ARF proteins in HER2-positive breast cancers	\$120,000/ 2 years <i>Funded in partnership with the Quebec Breast Cancer Foundation</i>  QUEBEC BREAST CANCER FOUNDATION
Côté, Jocelyn University of Ottawa	PRMT1 Alternatively Spliced Isoform v2 as a therapeutic target for breast cancer	\$120,000/ 2 years <i>Funded in partnership with the University of Ottawa</i>  uOttawa L'Université canadienne Canada's university

2015 Operating Grants Competition Results

Researcher	Project Title	Funding Details
Craig, Andrew Queen's University	Defining novel regulators of invadopodia and cancer metastasis	\$120,000/ 2 years
Davie, James CancerCare Manitoba	Role of ubiquitin carboxyl-terminal hydrolase isoenzyme 1 (UCHL1) in cancer genome organization and function	\$120,000/ 2 years <i>Funded in partnership with CancerCare Manitoba</i>  <i>All funds raised stay in Manitoba.</i>
Dedhar, Shoukat British Columbia Cancer Research Centre	Role of a novel LIMD2-ILK interaction in cancer progression and metastasis	\$120,000/ 2 years
DiNoia, JavierMarcelo Institut de recherches cliniques de Montréal	The relevance and function of protein arginine methyltransferase 5 in B cell neoplasms	\$120,000/ 2 years <i>Funded in partnership with the Bergeron-Jetté Foundation</i> 
Ding, Hao University of Manitoba	Function of RTEL1 DNA helicase in protecting cerebellar stem cells from medulloblastoma formation	\$119,990/ 2 years

2015 Operating Grants Competition Results


Researcher	Project Title	Funding Details
Emery, Gregory IRIC, Université de Montréal	Arf GAPs as regulators of the spatial distribution of molecular determinants controlling collective cell migration	\$120,000/ 2 years
Flamand, Louis Université Laval/CHU de Quebec Research Centre	Inherited chromosomally-integrated human herpesvirus 6 as a risk factor for breast cancer development	\$120,000/ 2 years
Foster, Paula University of Western Ontario	The use of novel <i>in vivo</i> imaging techniques to study the impact of a primary tumour on metastasis and dormancy	\$120,000/ 2 years
Gauthier, MarcA Institut national de la recherche scientifique (INRS)	Second generation molecular sieving coatings for improved treatment of leukemia using asparaginase	\$120,000/ 2 years <i>Funded in partnership with the C¹⁷ Council</i>
Gee, Stephen University of Ottawa	Characterization of DGK α and ζ Signaling to RhoC in Breast Cancer and investigation of their role in metastasis - Towards the development of novel therapeutics.	\$120,000/ 2 years





2015 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Giguère, Vincent</i> Rosalind & Morris Godman Cancer Research Centre	RINX1 as a key determinant of nuclear receptor signalling in poor outcome triple negative breast cancer	\$120,000/ 2 years
<i>Gingras, Anne-Claude</i> Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital	Mechanisms of phospho-recognition in the Hippo signaling pathway	\$120,000/ 2 years
<i>Gorski, Sharon</i> BC Cancer Agency	The role of LRRK2 in lung cancer	\$120,000/ 2 years
<i>Gotlieb, Walter H.</i> Jewish General Hospital	Sequential therapeutic targeting strategy of ovarian cancer harboring dysfunctional BRCA1.	\$119,900/2 years
<i>Gratton, Jean-Philippe</i> Université de Montréal	Role of PAK2 in angiopoietins/Tie2 signaling in endothelial cells and in angiogenesis.	\$120,000/ 2 years
<i>Guimond, Martin</i> Research Centre, Hôpital Maisonneuve-Rosemont	The therapeutic potential of SDF-1 α on graft-versus-host disease after allogeneic stem cell transplantation.	\$119,512/ 2 years


2015 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Hakem, Razqallah</i> University Health Network	DYRK1A and USP7: Regulation of Signaling Pathways and Involvement in Cancer	\$120,000/ 2 years
<i>Hebb, Matthew</i> Western University	<i>In vivo</i> validation of intratumoural modulation therapy for glioblastoma multiforme	\$119,650/ 2 years
<i>Hendzel, Michael</i> University of Alberta	The role of ATM compartmentalization in the G2/M checkpoint activation	\$120,000/ 2 years
<i>Hicks, Geoffrey</i> Manitoba Institute of Cell Biology and the University of Manitoba	FUS-dependent miRNA biogenesis coordinates the ATM DNA damage response and is disrupted in FUS associated cancer	\$120,000/ 2 years
<i>Hoang, Trang</i> IRIC, Université de Montréal	Effect of UM011997 on human T-acute lymphoblastic leukemia	\$120,000/ 2 years <i>Funded in partnership with the C¹⁷ Council</i> 



2015 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Hughes, Sarah</i> University of Alberta	Identification and characterization of novel post-transcriptionally regulated targets of the tumour suppressor protein Merlin in primary mammalian Schwann cells	\$119,237/ 2 years
<i>Ilangumaran, Subburaj</i> Université de Sherbrooke	Regulation of the fibrogenic response of hepatic stellate cells in hepatocellular carcinoma	\$120,000/ 2 years
<i>Jahroudi, Nadia</i> University of Alberta	Mechanism and function of de novo activation of von Willebrand factor gene expression in cancer cells	\$120,000/ 2 years <i>Funded in partnership with Alberta Innovates Health Solutions</i> 
<i>Jasmin, Bernard</i> University of Ottawa	Misregulation of the RNA-binding protein Staufen1 in rhabdomyosarcoma: Impact for pathogenesis and as a novel therapeutic target	\$120,000/ 2 years <i>Funded in partnership with the C¹⁷ Council</i> 




2015 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Kwok, Benjamin</i> IRIC, Université de Montréal	Targeting kinesin-13 family of microtubule depolymerases as a cancer therapeutic strategy	\$120,000/ 2 years
<i>Laprise, Patrick</i> Centre de recherche sur le Cancer, Université Laval	Molecular mechanisms supporting the CRB3-dependent repression of tumor growth and progression	\$119,620/ 2 years
<i>Larrivée, Bruno Bernard</i> Research Centre, Hôpital Maisonneuve-Rosemont	Promoting cancer therapy by BMP-mediated normalization of tumour blood vessels.	\$120,000/ 2 years
<i>Lecuyer, Eric</i> Institut de recherches cliniques de Montréal	Defining the mechanisms of RNA targeting to cancer cell-derived extracellular vesicles during epithelial to mesenchymal transitions.	\$120,000/ 2 years
<i>Lee, Cheng-Han</i> University of Alberta	Optimizing therapy to the molecular context of cancer - novel insights in endometrial cancer	\$120,000/ 2 years
<i>Lees-Miller, Susan</i> Cumming School of Medicine, University of Calgary	The role of Scaffold Attachment Factor A (SAF-A) phosphorylation in mitosis and breast cancer	\$120,000/ 2 years <i>Funded in partnership with Alberta Innovates Health Solutions</i> 



2015 Operating Grants Competition Results

Researcher	Project Title	Funding Details
Lees-Miller, Susan P. Cumming School of Medicine, University of Calgary	Effect of PARP inhibitors on ATM-deficient Pancreatic Cancer	\$120,000/ 2 years <i>Funded in partnership with Pancreatic Cancer Canada</i> 
Lesage, Sylvie Research Centre, Hopital Maisonneuve-Rosemont	Defining the anti-tumoral potential of pre-mNK cells	\$120,000/ 2 years
Ma, David University of Guelph	Examining the role of dietary fat, exercise and immune function in breast cancer	\$120,000/ 2 years <i>Funded by the Cancer Research Society's Environment-Cancer Fund™, in partnership with Read for the</i> 
Mahoney, Douglas University of Calgary	Smac-mimetic and oncolytic virus co-therapy for treating cancer	\$120,000/ 2 years
Major, François IRIC, Université de Montréal	Deciphering and targeting the gene interaction networks that shape cancer cells	\$120,000/ 2 years


2015 Operating Grants Competition Results

Researcher	Project Title	Funding Details
McGlade, Jane The Hospital for Sick Children	SLAP adaptor regulation of Cbl and tyrosine kinase signaling in leukemia.	\$120,000/ 2 years <i>Funded in partnership with the C¹⁷ council</i> 
McKenna, Sean University of Manitoba	Investigating the regulatory role of RNA-quadruplex helicases on telomerase activation.	\$118,600/ 2 years
Mes-Masson, Anne-Marie CHUM Research Centre	PARP inhibitor response in epithelial ovarian cancer: theranostic biomarkers and combination therapies.	\$120,000/ 2 years <i>Funded in partnership with Ovarian Cancer Canada</i> 
Mes-Masson, Anne-Marie CHUM Research Centre	Ovarian tumors on-chip : quantitative tools to predict chemoresponse using patient-specific proliferation assays	\$120,000/ 2 years
Miller, Jr, Wilson H. Lady Davis Institute	Inhibiting the metastatic propensity of pregnancy associated breast cancer (PABC) with inhibitors of eIF4E function.	\$118,342/ 2 years <i>Funded in partnership with CURE Foundation</i> 



2015 Operating Grants Competition Results

Researcher	Project Title	Funding Details
Morin, Gregg BC Cancer Agency	Targeting the regulation of DNA repair by CDK12 for ovarian cancer therapy	\$120,000/ 2 years
Nepveu, Alain McGill University	Resistance of cancer cells to mono-alkylating chemotherapies	\$120,000/ 2 years
Osornio Vargas, Alvaro University of Alberta	Mapping children's cancer and environmental carcinogenic emissions in Canada: an interdisciplinary spatio-temporal data mining approach	\$119,458/ 2 years <i>Funded by the Cancer Research Society's Environment-Cancer Fund™, in partnership with Read for the Cure</i>  
Park, Morag Goodman Cancer Research Centre, McGill University	Modelling poor outcome triple negative Breast Cancer	\$120,000/ 2 years
Penn, Linda Princess Margaret Cancer Centre, University Health Network	Identifying Oncogenic Interactors of Carcinogenic Myc Proteins	\$120,000/ 2 years





2015 Operating Grants Competition Results

Researcher	Project Title	Funding Details
<i>Petrecca, Kevin</i> Montreal Neurological Institute and Hospital	Establishing DRR as a master regulator of glioblastoma stem cells	\$120,000/ 2 years
<i>Schuermans, Carol</i> University of Calgary	Dissecting the roles of Etv5 and Ascl1 in oligodendroglomagenesis	\$120,000/ 2 years
<i>Siegel, Peter</i> Goodman Cancer Research Centre, McGill University	Deciphering cancer cell/neutrophil interactions during breast cancer liver metastasis.	\$120,000/ 2 years <i>Funded in partnership with CURE Foundation</i> 
<i>St-Pierre, Julie</i> McGill University	Role of the PGC-1 transcriptional coactivators in breast cancer progression	\$120,000/ 2 years
<i>Suh, Woong-Kyung</i> Institut de recherches cliniques de Montréal	Role of ICOS and SAP signalling in tumor progression of AITL (Angioimmunoblastic T cell lymphoma)	\$120,000/ 2 years

2015 Operating Grants Competition Results

Researcher	Project Title	Funding Details
Trinkle-Mulcahy, Laura University of Ottawa	Critical roles for the prognostic indicator Repo Man in promoting cancer progression	\$120,000/ 2 years <i>Funded in partnership with the University of Ottawa</i>  uOttawa L'Université canadienne Canada's university
Uniacke, Jim University of Guelph	The role of a hypoxic eIF4F complex in the translation of select mRNAs during tumour progression	\$120,000/ 2 years
Vanderhyden, Barbara Ottawa Hospital Research Institute	Determining the cell of origin of small cell cancer of the ovary, hypercalcemic type	\$120,000/ 2 years <i>Funded in partnership with Ovarian Cancer Canada</i>  Ovarian Cancer Canada Cancer de l'ovaire Canada
Weng, Andrew Terry Fox Laboratory, BC Cancer Agency	Intratumoral heterogeneity in follicular lymphoma: Insights into clonal evolution and transformation revealed by mass cytometry	\$120,000/ 2 years

2015 Operating Grants Competition Results

Researcher	Project Title	Funding Details
Wong, Philip Centre hospitalier de l'université de Montréal	Translating molecular science to soft-tissue sarcoma treatments	\$120,000/ 2 years
Woo, Minna Toronto General Research Institute	Novel metabolic role of BRCA1 in hepatocellular carcinoma	\$120,000/ 2 years <i>Funded by the Cancer Research Society's Environment-Cancer Fund™, in partnership with Read for the Cure</i>  
Young, Edmond University of Toronto	Development of an ex vivo Microfluidic Drug Sensitivity Cell-Based assay for Multiple Myeloma personalized therapy	\$120,000/ 2 years <i>Funded in partnership with Myeloma Canada</i>  MYELOMA CANADA <small>MAKING MYELOMA MATTER</small>
Zogopoulos, George Goodman Cancer Research Centre, McGill University	Preclinical trial evaluation of the poly(ADP-ribose) polymerase inhibitor 1/2 BMN 673 in pancreatic cancer associated with homology-directed DNA repair defects	\$120,000/ 2 years <i>Funded in partnership with the Ganotec / Marc-André Pigeon Memorial fund</i>  Ganotec / Marc-André Pigeon Fund